Drug Profile
Research programme: prolyl hydroxylase inhibitors - GlaxoSmithKline
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Amides; Quinazolines
- Mechanism of Action Procollagen-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anaemia in USA (PO)
- 26 Aug 2010 Preclinical trials in Anaemia in USA (PO)